COMMUNIQUÉS West-GlobeNewswire

Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025
02/05/2025
Tokyo, Japan and Cambridge, UK, 2 May 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2025 [...]
301,521 Orion Corporation A shares converted into B shares
02/05/2025
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 2 MAY 2025 at 9.00 EEST 301,521 Orion Corporation A shares converted into B shares In accordance with Section [...]
Idorsia issues invitation to the 2025 Annual General Meeting of Shareholders
02/05/2025
Allschwil, Switzerland – May 2, 2025 Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting to approve the [...]
OBI Pharma reçoit l’approbation de la FDA à la suite de sa demande d’étude clinique de la Phase I/II pour OBI-902, un CAM ciblant Trop-2
02/05/2025
OBI-902 est le premier CAM utilisant la technologie CAM brevetée GlycOBI® d’OBI TAIPEI, Taïwan, 02 mai 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (« OBI »), un laboratoire d’oncologie au stade clinique (4174.TWO), [...]
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
02/05/2025
Company Announcement Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE ® FL-1 trial Full results from the trial will be [...]
Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health
01/05/2025
Agreement will facilitate widespread distribution of NARCAN® Nasal Spray throughout Ontario WINNIPEG, Manitoba, May 01, 2025 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced a maximum three- [...]
Coherus to Participate in Upcoming Investor Conferences
01/05/2025
REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that the company will be webcasting its participation in the upcoming conferences: Citizens Life [...]
Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules
01/05/2025
FREEHOLD, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today [...]
Premier Health Announces Results of Shareholders’ Meeting
01/05/2025
MONTRÉAL, May 01, 2025 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “ Corporation ” or “ Premier Health ”), a leading Canadian Healthtech company, announces that all matters submitted to [...]
Precipio Announces Q1-2025 Shareholder Update Call
01/05/2025
Conference Call to be held on May 15th, 2025 at 5:00 PM EST NEW HAVEN, Conn., May 01, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q1-2025 corporate [...]
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01/05/2025
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for [...]
Primary Care Physician Use of Counterpart Assistant Technology Associated with Better Health Outcomes in Patients with Congestive Heart Failure
01/05/2025
New whitepaper highlights how a relationship with a Primary Care Physician (“PCP”) that uses Counterpart Assistant is associated with better clinical management, and fewer hospitalizations (18% lower) and readmissions ( [...]
Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025
01/05/2025
DEER PARK, Ill., May 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
MacroGenics to Participate in Upcoming Investor Conference
01/05/2025
ROCKVILLE, MD, May 01, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics [...]
Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K
01/05/2025
CARLSBAD, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it received an expected deficiency notification letter from the Listing Qualifications [...]
Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights
01/05/2025
– Company advances SL-325 program with an IND filing expected in the third quarter of 2025 – – Cash balance of approximately $60.9 million as of March 31, 2025, expected to fund operations into 2027 – AUSTIN, TX and [...]
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/05/2025
FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) [...]
Cytokinetics Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy
01/05/2025
SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act ( [...]
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/05/2025
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly- [...]

Pages